Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Marmarelis, Melina E., Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, and Patrick A. Ott. 2016. "Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma." Journal for Immunotherapy of Cancer 4 (1): 26. doi:10.1186/s40425-016-0129-x. http://dx.doi.org/10.1186/s40425-016-0129-x. |
|---|---|
| Published Version | doi:10.1186/s40425-016-0129-x |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860040 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to OtherPosted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

Melina E. Marmarelis1, Meredith R. Davis1, Nilay S. Sethi1, Katherine M. Krajewski2, Rana R. McKay1, Toni K. Choueiri1 and Patrick A. Ott1*

Abstract

Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor infiltrating lymphocytes, PD-L1 status, and mutational load may be equally or even more important in predicting clinical benefit from PD-1 pathway blockade than tumor histology. This case of a patient with concurrent metastatic melanoma and metastatic RCC, both of which were controlled for more than a year after a single dose of the anti-PD-1 antibody pembrolizumab, illustrates the potential to simultaneously treat distinct immunogenic tumors with anti-PD-1 agents.

Keywords: PD-1, Immune checkpoint blockade, Antibody therapy, Melanoma, Renal cell cancer, Immunotherapy, Concurrent cancer

Background

Immune checkpoint blockade using monoclonal antibodies directed against negative regulators such as cytotoxic lymphocyte antigen-4 (CTLA-4) and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has emerged as a powerful strategy in the treatment of different cancer types [1–3]. Both CTLA-4 and PD-1 are cell surface receptors that negatively regulate the immune response and their blockade can induce or enhance anti-tumor T cell activity. The anti-CTLA-4 monoclonal antibody ipilimumab demonstrated a survival benefit in Phase III studies for the first time in patients with advanced melanoma [2, 4], leading to approval in several countries. Durable tumor responses in patients with advanced melanoma being treated with ipilimumab yielded a plateau in the survival curve at 21 % 3 years out from study initiation [5]. Inhibition of the PD-1/PD-L1 pathway showed objective response rates of up to 40 % and superior overall survival when compared to ipilimumab in advanced melanoma [6]. Strikingly, as opposed to the relatively modest anti-tumor activity of ipilimumab outside of melanoma, PD-1 pathway inhibition is efficacious against a wide spectrum of solid and hematological malignancies including RCC, non-small cell lung cancer, bladder cancer, and Hodgkin’s lymphoma. There is evidence that tumor characteristics such as the presence of an immune cell infiltrate, expression of PD-L1 on tumor and/or immune cells, and an elevated mutational load with corresponding expression of neoantigens are predictive of anti-tumor activity with PD-1 pathway inhibition [7–10]. The broad anti-tumor activity of PD-1 pathway blockade suggests that it may be effective against different tumors present in one individual. These considerations may be critical in designing a treatment plan for a patient with metastases from different primary tumors, which poses a particular challenge in current cancer therapeutics. Here, we present a patient with concurrent metastatic melanoma and RCC who achieved disease control of both malignancies after a single dose of the anti-PD-1 monoclonal antibody pembrolizumab.
**Case presentation**

A 73-year-old man was diagnosed with T1a melanoma arising from the right shoulder in 2009. He underwent a wide excision and sentinel lymph node biopsy. Pathology review revealed a 1.64 mm melanoma, anatomic level deep III/early IV, no ulceration, 1 mitosis/mm². Four right axillary sentinel lymph nodes were negative for involvement with melanoma. In September 2013, after experiencing hematuria, the patient underwent a cystoscopy followed by transurethral resection of a bladder tumor (TURBT), which revealed a low-grade urothelial carcinoma with no evidence of bladder invasion. He is a lifelong non-smoker. A staging computerized tomography (CT) scan revealed two right lower lobe lung nodules (2.7 cm and <1 cm), and a 6.3 cm tumor in the left kidney. A positron emission tomography computerized tomography (PET/CT) in November 2013 (Fig. 1) showed enlarged mediastinal lymph nodes in addition to FDG uptake in the lung nodules and a complex left kidney mass. A mass in the thoracic spine (T3 vertebra) and a small focus of uptake in the right sacral ala were also

---

| Date       | Event                                      |
|------------|--------------------------------------------|
| 1/17/14    | Ipilimumab                                 |
| 2/7/14     | Ipilimumab + bevacizumab                   |
| 2/28/18    | Ipilimumab                                 |
| 3/21/14    | Ipilimumab                                 |
| 7/29/14    | Pembrolizumab, 2mg/kg x1                   |
| 8/19/14    | Pembrolizumab discontinued 2nd immune-related hepatitis |
| 11/11/13   | PET/CT: Enlarged mediastinal nodes, RLL lung nodule (path melanoma), complex left kidney mass, T3 vertebra lesion (pathology RCC) |
| 4/21/14    | PET/CT: Mixed response                     |
| 5/19/14    | PET/CT: SD                                 |
| 7/14/14    | PET/CT: Progressive disease (new adrenal lesion) |
| 11/24/14   | CT: PR/SD                                  |
| 2/23/15    | CT: PR/SD                                  |
| 8/26/15    | CT: PR/SD                                  |
| 5/20/15    | CT: PR/SD                                  |
| 11/10/15   | CT: PD                                     |

**Fig. 1** Timeline of events and treatment. CT = computerized tomography. PET = positron emission tomography. RLL = right lower lobe. RCC = renal cell carcinoma

---

![Fig. 2 a](image-a.png) PET CT demonstrating FDG uptake in an enlarged mediastinal lymph nodes, small right lower lobe lung nodule, exophytic heterogenous mass in left kidney and a 3.5 x 3.2 cm vertebral mass at T3 with SUV of 11.4. **b** Enhanced CT view of the T3 vertebral mass
noted (Fig. 2). A biopsy of the T3 vertebral lesion was performed and pathologic review demonstrated RCC. A core needle biopsy of one of the right lower lobe lung nodules was also performed and unexpectedly revealed recurrent metastatic melanoma (Fig. 3). In December 2013, a brain MRI showed a subcentimeter left temporal metastasis. The patient received radiation to the T3 vertebral metastasis and stereotactic radiosurgery to the brain metastasis.

While weighing the treatment options for these two cancers, although our initial thoughts were to focus on the more aggressive melanoma (BRAF and NRAS wild type), we were motivated to design a therapy regimen that could yield efficacious responses against both cancers. Bevacizumab, the anti-Vascular Endothelial Derived Growth Factor (VEGF) directed monoclonal antibody approved for use in renal cell carcinoma, has some efficacy in advanced melanoma and was found to be safe and potentially synergistic with ipilimumab [11, 12]. The urothelial cancer was not addressed therapeutically because of the metastatic melanoma and RCC taking precedence. Based on this data, the patient received one cycle of ipilimumab at the standard dose of 3 mg/kg. Following insurance approval, he then received a cycle of ipilimumab in combination with bevacizumab 15 mg/kg every 3 weeks. Shortly after receiving the combination, the patient presented with a left sided headache, blurred vision in the left eye, and left eyelid ptosis. A brain MRI revealed a subacute hemorrhage at the site of the previously irradiated left temporal metastasis. A temporal artery biopsy was negative for temporal arteritis. The remainder of ipilimumab therapy (3rd and 4th dose) was administered without concurrent Bevacizumab given the concern that VEGF inhibition may have possibly contributed to the brain hemorrhage. The ipilimumab treatment course was also complicated by immune-related hypophysitis resulting in adrenal insufficiency, which was successfully treated with hydrocortisone.

Serial PET/CTs showed progressive disease in April 2014. Repeat PET/CT performed in July of 2014 once again revealed disease evolution with increased FDG avidity of a dominant right lower lobe lung mass, increased size and avidity of a right adrenal lesion, and increased FDG avidity of the left sided renal mass. Based on these results and the availability on an Expanded Access Program, treatment with the anti-PD-1 antibody pembrolizumab at 2 mg/kg every 3 weeks was initiated in July of 2014. After

---

**Fig. 3** Pathology of T3 vertebral mass and right lower lobe lung lesions. Pathology of the T3 vertebral mass biopsy represents a metastasis from renal cell carcinoma, the lung lesion is consistent with a metastasis from melanoma. (1) Immunohistochemistry markers of the T3 vertebral mass and the right lower lobe (RLL) lung nodule. (2) T3 vertebral lesion: a. low power b. high power c. CAM5.2 d. Pax-8 (3) RLL lesion: a. high power b. Cytokeratin (CK7) c. S100 d. Melan-A e. HMB45

---

![Table](image-url)
one dose, the patient developed grade 3 transaminitis (ALT > 7x ULN, AST > 11x ULN, total bilirubin normal), prompting discontinuation of treatment due to presumed immune-related hepatitis. Intravenous solumedrol was administered for the treatment of immune-related hepatitis. A liver biopsy performed six days into the steroid taper (prednisone 80 mg BID for the six days prior to biopsy) showed pathological features compatible with but not diagnostic of immune-related hepatitis. Liver function tests normalized fifteen days after the initial diagnosis and remained within reference range after completion of a four-week prednisone taper.

Restaging CTs of the chest, abdomen, and pelvis performed in September 2014 demonstrated dramatic reduction in size of several lung metastases, while others remained stable. The right adrenal lesion, several mesenteric nodules, and a subcutaneous nodule on the left anterior abdominal wall were all substantially smaller in size. The left renal mass remained stable. Serial CTs of the chest, abdomen, and pelvis in November 2014, February 2015, May 2015, and August 2014 showed continued decrease in tumor size consistent with a partial response to treatment for a duration of 14 months (Fig. 4). Most recently, a chest, abdomen, and pelvic CT in November of 2015 showed two new subcentimeter pulmonary lesions and a satellite nodule in the primary renal cell cancer. The patient is currently undergoing re-induction therapy with pembrolizumab.

**Conclusion**

We describe a patient with concurrent biopsy-proven metastatic melanoma and RCC who was treated with one dose of pembrolizumab that was complicated by immune-related hepatitis but nevertheless lead to a durable tumor response in both melanoma and RCC.

While the presence of two distinct metastatic processes was established by biopsy (melanoma in the lung and RCC in the spine at level T3), the contribution of each tumor to the overall metastatic burden cannot be determined. However, since at least one (and likely more) lung lesion(s) represent melanoma and the left renal lesion represent RCC by imaging criteria, ongoing disease control of both cancers was evident on serial imaging. It is notable that the patient developed immune-related hepatitis after only one dose of pembrolizumab. Immune-related toxicity may be associated with a favorable outcome in patients treated with CTLA-4 and/or PD-1 inhibition [13].

Multiple primary cancers, which is defined as the development of another primary cancer after diagnosis of an initial one (index cancer) in a given individual, is a relatively common occurrence. Interestingly, urinary bladder cancer is the most frequent index cancer in

---

**Fig. 4 a** PET CT images of the mediastinal mass, pulmonary lesion and renal mass. Left column: Pre- pembrolizumab; right column: 8 weeks after administration of one dose of pembrolizumab. There is near complete involution of the anterior mediastinal mass and a decrease in size of the pulmonary lesion. The size of the renal mass is unchanged. **b** Size (cm) on axial imaging (CT or PET/CT) of renal, mediastinal and dominant right pulmonary nodule over time. The last scan showed two new subcentimeter pulmonary metastases and increased size of a soft tissue component of the left renal mass.
patients with multiple primary cancers (18%), whereas 10% of patients with RCC and melanoma, respectively, develop a second primary [14]. No reliable data are available, to our knowledge, on frequencies of multiple primaries that have metastasized concurrently such as in our patient. It is interesting in this context that the patient's diagnosis of a localized low grade urothelial carcinoma of the bladder immediately preceded the patient's diagnosis of metastatic melanoma and RCC. While the non-muscle invasive bladder cancer lead to the diagnosis of melanoma and RCC in our patient, it appears unlikely that the bladder cancer contributed to the metastatic disease burden in this patient. Since bladder cancer has also been found to be responsive to PD-1 pathway inhibition, the possibility that a third solid tumor may also have been controlled by PD-1 blockade in our patient is nevertheless an intriguing consideration [8].

PD-1 blockade reverts the PD-1 receptor-mediated dysfunctional state of effector memory T cells that have infiltrated the tumor into an active, functional state, thereby enabling tumor cell killing. These T cells are presumably endogenously primed and specific for antigens expressed on the respective tumor they traffic into. It therefore appears more likely that these T cells recognize tumor antigens that are distinct between the melanoma and the RCC rather than shared antigens. Although the immune response may be distinct in RCC and melanoma, a certain percentage of these tumors are immunogenic and therefore potentially responsive to immune checkpoint blockade [15]. This case illustrates that despite these distinct immune responses, PD-1 inhibition may be a suitable treatment option for patients with concurrent immune-responsive cancers.

**Consent**

Clinical data for this case report were collected under institutional review board approval (Dana-Farber/Harvard Cancer Center #05-042).

**Consent to publish**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

**Abbreviations**

CT: computed tomography; CTLA-4: cytotoxic lymphocyte antigen-4; MRI: Magnetic Resonance Imaging; PD-1: immunological checkpoint programmed death; PD-L1: programmed death ligand 1; PET/CT: Positron emission tomography computerized tomography; RCC: renal cell carcinoma; TURBT: transurethral resection of a bladder tumor; VEGF: Vascular Endothelial Derived Growth Factor.

**Competing interests**

TKC reports grants from Bristol-Myers Squibb, grants and personal fees from GlaxoSmithKline, grants and personal fees from Novartis, grants from Exelixis, Inc., grants and personal fees from Pfizer, grants and personal fees from Merck, grants from Roche, and grants and personal fees from AstraZeneca, grants from TRACON Pharmaceuticals, grants from Peloton, personal fees from Bayer, personal fees from Prometheus outside the submitted work. PAO reports grants and personal fees from Bristol-Myers Squibb, personal fees from Amgen, and grants from Merck and AstraZeneca/MeDiImmune outside of the submitted work. All other authors have no conflicts to disclose.

**Authors’ contributions**

Author MM drafted the manuscript. MD helped to draft the manuscript and participated in the care of the patient. NS helped to draft the manuscript and participated in the care of the patient. KMK provided and analyzed data and helped to draft the manuscript, RM helped to draft the manuscript and participated in the care of the patient. TKC helped to coordinate the care of the patient and helped to draft the manuscript. PAO conceived of the report, helped to draft the manuscript, and coordinated the care for the patient. All authors read and approved the manuscript.

**Acknowledgement**

We thank Michelle Hirsch for providing pathology expertise and helpful discussions and Jonathan Nowak for providing the pathology images included in the paper.

**Author details**

1. Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA.
2. Department of Imaging, Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA.

**Received:** 12 January 2016  **Accepted:** 4 April 2016  **Published online:** 19 April 2016

**References**

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
2. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
3. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2013;366(26):2443–54.
4. Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
5. Schadenfroth D et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889–94.
6. Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.
7. Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
8. Herbst RS et al. Predictive correlates of response to the anti-PD-1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
9. Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med. 2015;372(8):783.
10. Ribz NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.
11. Kim KB et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34–41.
12. Hodi FS et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–42.
13. Postow MA et al. Nivolumab and Ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(20):2006–17.
14. Hayat MU et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37.
15. McDermott DF et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase I/II Study. J Clin Oncol. 2016;34(8):833–42.